Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 3176 2023-07-18 18:28:32 |
2 layout Meta information modification 3176 2023-07-19 03:28:38 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Del Giudice, L.; Pontieri, P.; Aletta, M.; Calcagnile, M. Mitochondrial Neurodegenerative Diseases. Encyclopedia. Available online: (accessed on 13 June 2024).
Del Giudice L, Pontieri P, Aletta M, Calcagnile M. Mitochondrial Neurodegenerative Diseases. Encyclopedia. Available at: Accessed June 13, 2024.
Del Giudice, Luigi, Paola Pontieri, Mariarosaria Aletta, Matteo Calcagnile. "Mitochondrial Neurodegenerative Diseases" Encyclopedia, (accessed June 13, 2024).
Del Giudice, L., Pontieri, P., Aletta, M., & Calcagnile, M. (2023, July 18). Mitochondrial Neurodegenerative Diseases. In Encyclopedia.
Del Giudice, Luigi, et al. "Mitochondrial Neurodegenerative Diseases." Encyclopedia. Web. 18 July, 2023.
Mitochondrial Neurodegenerative Diseases

Neurodegenerative diseases are characterized by the progressive degeneration of nerve cells. Some neurodegenerative diseases such as Alzheimer’s and Parkinson’s are caused by disorders in the mitochondria, which are organelles present in the eukaryotic cells of animals, plants and fungi, and their function is to produce energy.

mitochondrial neurodegenerative diseases mitochondrial ribosomal proteins MRPL44 NAM9 GEP3

1. Introduction

Luft et al. published in 1962 the first case of mitochondrial dysfunction in a 35-year-old woman affected by myopathy [1]. Since then, there has been a continuous advancement of research that is leading to the understanding, from a medical perspective, of the role of mitochondria in health, diseases and aging. Many seemingly unrelated pathologies, such as neuropathies, Alzheimer’s, Parkinson’s, myopathies, ataxia, cancer and others, share common underlying pathophysiological procedures. These mechanisms include the production of reactive oxygen species (ROS) and the damage they cause to the mitochondrial genome, leading to mitochondrial dysfunction [2][3][4]. As mitochondrial formation arises from the contribution of two distinct genomes, namely the nuclear DNA (nDNA) and the mitochondrial DNA (mtDNA) [5][6][7], genetic mutations in either the nDNA or the mtDNA, as well as genetic deletions in the mtDNA, can give rise to mitochondrial disease. These genetic mutations specifically result in defects in the mitochondrial oxidative phosphorylation system (OXPHOS) [8], which are the underlying cause of mitochondrial diseases [9][10][11]. Extensive research has been conducted on mutations occurring in nuclear genes associated with mitochondrial disorders, specifically focusing on their connection to diseases associated with premature aging [12][13] and POLG-related disorders that exhibit neurological symptoms [3][14][15]. Mitochondrial diseases represent the most common group of inherited metabolic dysfunction and are among the most prevalent types of inherited neurological disorders [16]. Mitochondrial disorders resulting from recurrent mutations in mtDNA manifest as shared syndromes across unrelated families and populations [2][17]. These disorders exhibit a wide range of clinical variations and can emerge at any age [16]. Given that mitochondria exist in all cells of the body except for red blood cells, the resulting clinical symptoms may manifest in specific organs independently but frequently involve multiple systems in organs that have high energy requirements, such as the brain, skeletal system, muscles and heart [16]. With reference to mutations in mtDNA or nDNA, from the point of view of clinical diagnosis, primary mitochondrial disease (PMD) and secondary mitochondrial dysfunction (SMD) are distinguished [18][19]. The primary differentiation between PMD and SMD lies in the fact that PMD genes either directly encode OXPHOS proteins or influence OXPHOS function by affecting the production of the complex machinery required for the OXPHOS process. On the other hand, SMD can be caused by genes that do not encode OXPHOS proteins or affect their production. SMD is often associated with various hereditary nonmitochondrial diseases [11][18][19]. There are several factors that determine the onset of mitochondrial dysfunction such as age, heredity factors, an unhealthy lifestyle or stress, environmental toxicity and more [7][16][20][21][22][23][24]. Among the mitochondrial diseases, the most widely known are neurodegenerative diseases, which are mainly caused by genetic factors and by environmental factors [7][24][25]. Neurodegenerative diseases are stress-inducing brain disorders characterized by behavioral, motor and cognitive impairments. Numerous studies conducted over the years have provided evidence that mitochondrial dysfunction serves as the underlying cause in the development of neurodegenerative diseases, which include Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), Amyotrophic Lateral Sclerosis (ALS) and Dementia [26][27][28][29]. These diseases arise from deficiencies in mitochondrial function, which is primarily regulated by over 1000 proteins encoded by both the mitochondrial and nuclear genomes [30]. Studies have shown that the majority, around 90%, of mitochondrial proteins are encoded by genes found in the cell nucleus. These proteins are synthesized by ribosomes in the cytosol and subsequently transported into mitochondria through a complex import machinery composed of multiple components [5][6][31][32][33][34]. These proteins have various functions attributed to them, including respiration, metabolite transport, protein translocation, redox homeostasis and other processes that are interconnected within complex and dynamic networks. The malfunctioning of these systems could lead to the development of diseases [35]. Despite mitochondria having their own genome, many nuclear-encoded mitochondrial ribosomal proteins (MRPs) are essential for proper organelle function. Mutations in Mrp genes, as indispensable components of the mitochondrial translation machinery, are detrimental to the OXPHOS system and associated with several neurodegenerative diseases in humans [36][37][38][39].

2. Mitochondrial Neurodegenerative Diseases

The human mitochondrial genome consists of a circular molecular structure comprising approximately 16,569 pairs of nucleotides (Figure 1). It contains a total of 24 mtDNA genes, including the small ribosomal RNA (12S rRNA) and large ribosomal RNA (16S rRNA) genes, as well as 22 transfer RNA (tRNA) genes necessary for translating the 13 respiratory chain proteins [19][40][41].
Studies conducted over the past forty years have highlighted the role of mitochondria in both normal brain function and the pathogenesis of diseases originating from them (Table 1) [42]. Mitochondrial diseases result from hereditary or spontaneous mutations in mtDNA or nDNA, leading to abnormalities in the functions of proteins or RNA molecules typically found within mitochondria [40][43][44]. Generally, the term “mitochondrial disease” describes a heterogeneous set of conditions caused by genetic defects in the assembly and/or function of OXPHOS proteins [44]. In fact, mitochondria play a fundamental role in energy production and are essential in numerous cellular processes [35][45]. Consequently, mitochondrial dysfunction often propagates and/or underlies many pathological states, including neurodegenerative diseases [46][47] and the aging process [48][49]. More recently, extensive research efforts have helped define some of the pathological mechanisms underlying neurodegenerative processes, such as the two most common neurodegenerative disorders: AD and PD.
Table 1. Mitochondrial diseases a.
Figure 1. Schematic map of the human mitochondrial genome with related neurodegeneration diseases (adapted with minor modification from [2][19], CO: cytochrome oxidase (COX) subunit genes; CYTb = cytochrome b; ND = OXPHOS complex I subunit genes; D-loop = noncoding displacement loop or control region; AD-PD = neurodegenerative diseases: Alzheimer’s disease and Parkinson’s disease. Image generated with OGDRAW [82].

2.1. Alzheimer’s Disease in Brief

AD, a neurodegenerative condition linked to the aging process, is characterized by progressive cognitive and memory decline. It stands as the most prevalent neurodegenerative disorder, comprising around 60–70% of all dementia cases and impacting approximately 6% of individuals aged 65 and above (referred to as late-onset AD). Furthermore, a smaller subset of patients, around 2–10%, experience early-onset AD [40][83][84]. At the cellular level, AD is characterized by progressive and irreversible deterioration of neuronal structure and function in specific brain regions, including the hippocampus and neocortical areas, leading to cognitive dysfunction and dementia [85]. The main neuropathological features of the disease include the presence of extracellular β-amyloid plaques and intracellular neurofibrillary tangles formed by hyperphosphorylated tau proteins [86][87][88]. The causal relationship between the presence of these two hallmarks and AD is still not fully understood. It remains uncertain whether they are the primary cause of the disease or predominantly the outcome of a cascade of cellular events, including oxidative stress, mitochondrial dysfunction and apoptosis. Nonetheless, the exact mechanism by which these proteins damage neurons is still unknown [87][89]. Despite AD being the leading cause of dementia worldwide and the growing population of AD patients, no new therapies have received approval for over a decade [90][91].

2.2. Parkinson’s Disease in Brief

PD is the most common movement disorder and the second most frequent age-related neurodegenerative disorder in the world after AD [92][93]. It is a progressive and irreversible pathology characterized by significant neuronal loss in the pars compacta of the substantia nigra, leading to an alteration in dopaminergic transmission [94][95] and the presence of intracellular inclusions called Lewy bodies, which contain aggregates of α-synuclein [96][97]. The disease’s etiology is attributed to a combination of genetic and environmental factors [96]. In large populations, 5–10% of PD cases are attributed to known PD genes, indicating monogenic PD. However, 90 genetic risk variants collectively contribute only 16–36% to the genetic risk of nonmonogenic PD [93]. From a genetic standpoint, definitively characterized PD genes include autosomal dominant forms (SNCA, LRRK2 and VPS35) and autosomal recessive forms (PRKN, PINK1 and DJ1). Additionally, mutations in genes such as ATP13A2, DCTN1, DNAJC6, FBXO7, PLA2G6 and SYNJ1 have been associated with atypical or complex parkinsonism. Furthermore, recent studies have identified several other genes, including CHCHD2, LRP10, TMEM230, UQCRC1 and VPS13C, that are implicated in PD [76][98]. Besides core motor features such as bradykinesia (slowness of movement), rigidity and resting tremor, PD is also associated with a heterogeneous spectrum of nonmotor symptoms that significantly contribute to the overall disease burden of PD [99]. From a clinical perspective, there is no definitive method to diagnose PD in vivo, except for genetic testing in specific circumstances, which is limited to a few cases. Given the protracted timeline over which PD can advance, it imposes significant and far-reaching implications on patients, healthcare providers and society at large [93].

3. Mitochondrial Ribosomal Proteins Associated with Mitochondrial Neurodegenerative Diseases

Ribosomes are macromolecular machines with a universally conserved structure and function for protein synthesis. Within the cells of living organisms, mitochondria contain their own ribosomes, known as mitoribosomes, which are primarily responsible for synthesizing essential components of the oxidative phosphorylation machinery [40][100]. Mitoribosomes are located in the organelle matrix and are associated with the inner membrane to facilitate the cotranslational insertion of highly hydrophobic nascent polypeptides [38][101]. In mammals, mtDNA encodes 13 proteins that serve as crucial membrane components of the OXPHOS enzymatic complexes. The mammalian mitoribosome is a 55S ribonucleoprotein complex composed of a 39S large subunit (mt-LSU) containing 52 (MRPs), a 16S rRNA and a structural tRNA (tRNAVal in human cells), as well as a 28S small subunit (mt-SSU) with 30 MRPs and a 12S rRNA. In comparison to bacterial and eukaryotic cytoplasmic ribosomes, the 55S ribosomes contain a lower proportion of RNA, approximately 25–30% [102][103]. All MRPs are encoded in nDNA, synthesized using cytoplasmic ribosomes, and subsequently imported into the mitochondrial matrix. Once inside, they are assembled with subunit-specific RNAs encoded in mtDNA [40][103][104][105][106]. Dysfunctions in mitochondrial translation can lead to severe human diseases and may result from mutations in various components of the mitochondrial translation machinery, including tRNAs, aminoacyl-tRNA synthetases, translation factors and ribosomal components [2][107][108]. Furthermore, mutations or deficiencies in ribosome assembly proteins or other essential proteins can also contribute to mitochondrial diseases, as the mitochondrial ribosome is responsible for translating mRNAs for the 13 essential proteins of the OXPHOS system in affected tissues. Several MRP genes are located in loci associated with disorders related to impaired oxidative phosphorylation, such as Leigh syndrome, multiple mitochondrial dysfunctions and nonsyndromic hearing loss. Therefore, these diseases exhibit genetic heterogeneity and can manifest in a broad spectrum of clinical presentations [37][38][40][106][109][110]. The presence of numerous patients affected by mitochondrial disorders, characterized by multienzymatic OXPHOS defects of unknown genetic origin, suggests that there are still many genes involved in the biogenesis and function of the mitochondrial translation machinery that remain unidentified. Regarding alterations in ribosomal components associated with human diseases, only a limited number of mutations in mitoribosomal proteins have been reported so far [36][38][111]. In recent publications, the focus has been on the detection of pathological mutations in nuclear genes responsible for encoding mitochondrial ribosomal proteins. These findings emphasize the significance of their expression and involvement in mitochondrial translation, thus suggesting their potential role as contributing factors to genetic neurodegenerative diseases in humans [7][16][38][40][111][112][113].

4. Three Mitochondrial Ribosomal Proteins as Intermediate Stage in a Path Connected with Alzheimer’s and Parkinson’s

Neurodegenerative disorders are characterized by a gradual and progressive decline, specifically targeting interconnected neuronal systems based on anatomical or physiological relationships [114]. Mitochondria play a critical role in generating the majority of cellular ATP and are indispensable for ensuring optimal neuronal functioning. Dysfunction of mitochondria can give rise to PMDs and potentially contribute to the development of neurodegenerative conditions such as AD and PD. Mitochondria serve as crucial regulators of both cell survival and cell death, exerting a central influence on the aging process, and have been observed to interact with numerous specific proteins associated with genetic forms of neurodegenerative diseases [115]. These diseases include AD, PD, ALS and HD [114][116].

4.1. The Pathophysiology of Mitochondrial Diseases

The pathophysiology of mitochondrial diseases is complex and involves genetic mutations in both mtDNA and nDNA. Mitochondrial diseases are typically considered to be disorders caused by biochemical defects in the respiratory chain [116][117]. The regulatory role of nuclear genes in maintaining mitochondrial homeostasis and functionality is now included, along with defects in the lipid milieu, mitochondrial translation and mitochondrial fission and fusion [100][116][117]. Considerable progress has been made in the understanding of the molecular basis of mitochondrial diseases and their genetic etiology, particularly through next-generation sequencing/whole exome sequencing (NGS/WES) approaches. These approaches provide valuable information on the genes implicated in neurodegenerative disorders and could better define the impact of mitochondrial dysfunction on their pathogenesis [118]. As previously mentioned, mitochondrial diseases were caused as a consequence of mutations, whether inherited or spontaneous, in either mtDNA or nDNA. Furthermore, as previously discussed, human cells possess two distinct genomes and two protein synthesis systems. The first genome is the nuclear genome (nDNA), which consists of approximately 3 × 109 base pairs, and a second genome resides within a cytoplasmic organelle known as the mitochondrion (mt). Approximately 1500 nuclear gene products (around 3% of the total) are translated by cytoplasmic ribosomes and subsequently imported into the mitochondrion to perform their functions [119][120]. The cytoplasmic ribosome is composed of four rRNAs (28S, 18S, 5.8S and 5S) and 85 ribosomal proteins. The genes responsible for encoding these components have been mapped and investigated to a considerable extent [121]. Ribosomes play a crucial role as molecular machines, essential for all life on our planet. They decode information carried by messenger RNAs (mRNAs) and translate it into proteins [122]. Ribosome biogenesis is the crucial process in which all the components of ribosomes, such as ribosomal proteins (r-proteins) and rRNAs, come together to form the functional translation machinery. This process involves a large number of proteins, known as maturation factors and RNA factors (such as snoRNAs in cytosolic ribosome maturation) that aid in properly folding, assembling and modifying the different elements of the ribosome [123]. In mitochondria, the process of mitoribosome biogenesis is even more complex due to the need for coordination between two gene expression compartments [124]. Several mutations have been discovered in genes related to the cytoplasmic translation machinery, including ribosome components and numerous interacting factors. These mutations have been linked to various human diseases. On the contrary, genes from both the nuclear and mitochondrial genomes contribute to the formation of mitochondrial ribosomes, also known as mitoribosomes. These mitoribosomes play a crucial role in the synthesis of the oxidative phosphorylation machinery. These genes have been the subject of major research efforts in yeast and humans. Yeast serves as a model system for eukaryotic cell biology, while in humans, mitoribosomes have been implicated in human health [125]. The synthesis of ribosomal proteins occurs on cytoplasmic ribosomes, after which they are imported into the mitochondria. Interference with the synthesis of these proteins and other components of the mitochondrial translation system, such as mitochondrial tRNAs, either through deletion or mutation of the mitochondrial genes, is known to cause various mitochondrial diseases of varying severity. These diseases include myopathies and sensorineural disorders such as blindness and deafness [126]. By analogy, it can be expected that the loss or mutation of any of the 78 proteins required for the function of the mitochondrial ribosome [127] would also result in mitochondrial disease. Published research indicates that certain genes responsible for encoding MRPs are located within chromosomal loci that have already been associated with human disorders, including conditions like deafness, retinitis pigmentosa and Usher syndrome 1E [128]. A number of mutations that affect mitochondrial translation have been identified, including mutations in the core MRPs: MRPS16, MRPS22 and MRPL12 [129]. Additionally, mutations have been found in several accessory proteins, such as ObgH1 and C7orf30 [129]. It appears that mutations in MRPS16 and MRPS22 impact the stability of the mitoribosome [129], while MRPL12 is involved in the recruitment of elongation factors and the modulation of mitochondrial gene expression [128].

4.2. The Connection between Mitochondrial Dysfunctions and the Effects of Heavy Metals and Metalloid Oxyanions

Extensive scientific evidence has established a connection between mitochondrial dysfunctions, the harmful effects of heavy metals and metalloid oxyanions and systemic as well as neurodegenerative disorders [130][131]. Specifically, the toxicity of the metalloid tellurium (Te) has been implicated in the etiopathogenesis of various neurodegenerative disorders [131][132]. Accumulated experimental data indicate that tellurium not only exhibits a well-documented garlic-like odor but also exerts significant neurotoxic effects. In the past, Te has been employed as a valuable tool for studying the evolutionary origins of mitochondria in prokaryotes [133]. Mutations in these genes result in resistance to Te in the yeast S. cerevisiae. Additionally, previous publications have associated the toxic effects of Te with the development of neurodegenerative diseases like AD and PD [131][132]. The recent work by Pontieri et al. [134] represents a significant advancement in scientific knowledge regarding the study of the three MRPs involved in potassium Te resistance in S. cerevisiae. It sheds light on their potential role in neurodegenerative dysfunctions such as AD or PD, thus providing valuable insights for further investigation.


  1. Luft, R.; Ikkos, D.; Palmieri, G.; Ernster, L.; Afzelius, B. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: A correlated clinical, biochemical, and morphological study. J. Clin. Investig. 1962, 41, 1776–1804.
  2. Wallace, D.C. The mitochondrial genome in human adaptive radiation and disease: On the road to therapeutics and performance enhancement. Gene 2005, 354, 169–180.
  3. Longley, M.J.; Graziewicz, M.A.; Bienstock, R.J.; Copeland, W.C. Consequences of mutations in human DNA polymerase gamma. Gene 2005, 354, 125–131.
  4. Pieczenik, S.R.; Neustadt, J. Mitochondrial dysfunction and molecular pathways of disease. Exp. Mol. Pathol. 2007, 83, 84–92.
  5. Dujon, B. Mitochondrial genetics and functions. In Molecular Biology of the Yeast Saccharomyces cerevisiae: Life Cycle and Inheritance; Strathern, J.N., Jones, E.W., Broach, J.R., Eds.; Cold Spring Harbor Laboratory, Cold Spring Harbor: New York, NY, USA, 1981; pp. 505–635.
  6. Wolf, K.; Del Giudice, L. The variable mitochondrial genome of ascomycetes: Organization, mutational alterations, and expression. Adv. Genet. 1988, 25, 185–309.
  7. Craven, L.; Alston, C.L.; Taylor, R.W.; Turnbull, D.M. Recent Advances in Mitochondrial Disease. Annu. Rev. Genom. Hum. Genet. 2017, 18, 257–275.
  8. Chance, B.; Sies, H.; Boveris, A. Hydroperoxide metabolism in mammalian organs. Physiol. Rev. 1979, 59, 527–605.
  9. Spinazzola, A.; Zeviani, M. Disorders from perturbations of nuclear-mitochondrial intergenomic cross-talk. J. Intern. Med. 2009, 265, 174–192.
  10. Chen, C.; Chen, Y.; Guan, M.X. A peep into mitochondrial disorder: Multifaceted from mitochondrial DNA mutations to nuclear gene modulation. Protein Cell 2015, 6, 862–870.
  11. Mahmud, S.; Biswas, S.; Afrose, S.; Mita, M.A.; Hasan, M.R.; Shimu, M.S.S.; Paul, G.K.; Chung, S.; Saleh, M.A.; Alshehri, S.; et al. Use of Next-Generation Sequencing for Identifying Mitochondrial Disorders. Curr. Issues Mol. Biol. 2022, 44, 1127–1148.
  12. Scheibye-Knudsen, M.; Scheibye-Alsing, K.; Canugovi, C.; Croteau, D.L.; Bohr, V.A. A novel diagnostic tool reveals mitochondrial pathology in human diseases and aging. Aging 2013, 5, 192–208.
  13. Fang, E.F.; Scheibye-Knudsen, M.; Brace, L.E.; Kassahun, H.; SenGupta, T.; Nilsen, H.; Mitchell, J.R.; Croteau, D.L.; Bohr, V.A. Defective mitophagy in XPA via PARP1 hyperactivation and NAD+/SIRT1 reduction. Cell 2014, 157, 882–896.
  14. Hudson, G.; Chinnery, P.F. Mitochondrial DNA polymerase gamma and human disease. Hum. Mol. Genet. 2006, 15, R244–R252.
  15. Rahman, S.; Copeland, W.C. POLG-related disorders and their neurological manifestations. Nat. Rev. Neurol. 2019, 15, 40–52.
  16. Gorman, G.S.; Chinnery, P.F.; Di Mauro, S.; Hirano, M.; Koga, Y.; McFarland, R.; Suomalainen, A.; Thorburn, D.R.; Zeviani, M.; Turnbull, D.M. Mitochondrial diseases. Nat. Rev. Dis. Prim. 2016, 2, 16080.
  17. Spinazzola, A.; Zeviani, M. Disorders of nuclear mitochondrial intergenomic signaling. Gene 2005, 354, 162–168.
  18. Niyazov, D.M.; Kahler, S.G.; Frye, R.E. Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment. Mol. Syndromol. 2016, 7, 122–137.
  19. Chinnery, P.F. Primary Mitochondrial Disorders Overview 1. In Clinical Characteristics of Mitochondrial Disorders; GeneReviews: Seattle, DC, USA, 2021; pp. 1–16.
  20. Singh, K.K. Mitochondrial dysfunction is a common phenotype in aging and cancer. Ann. N. Y. Acad. Sci. 2004, 1019, 260–264.
  21. Youle, R.J.; van der Bliek, A.M. Mitochondrial Fission, Fusion, and Stress. Science 2012, 337, 1062–1065.
  22. Kudryavtseva, A.V.; Krasnov, G.S.; Dmitriev, A.A.; Alekseev, B.Y.; Kardymon, O.L.; Sadritdinova, A.F.; Fedorova, M.S.; Pokrovsky, A.V.; Melnikova, N.V.; Kaprin, A.D.; et al. Mitochondrial dysfunction and oxidative stress in aging and cancer. Oncotarget 2016, 7, 44879–44905.
  23. Will, Y.; Dykens, J.A. Mitochondrial Dysfunction by Drug and Environmental Toxicants; John Wiley & Sons Limited: New York, NY, USA, 2018.
  24. Meyer, J.N.; Hartman, J.H.; Mello, D.F. Mitochondrial Toxicity. Toxicol. Sci. 2018, 162, 15–23.
  25. Vodičková, A.; Koren, S.A.; Wojtovich, A.P. Site-specific mitochondrial dysfunction in neurodegeneration. Mitochondrion 2022, 64, 1–18.
  26. Gibson, G.E.; Starkov, A.; Blass, J.P.; Ratan, R.R.; Beal, M.F. Cause and consequence: Mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochim. Biophys. Acta 2010, 1802, 122–134.
  27. Chaturvedi, R.K.; Flint Beal, M. Mitochondrial diseases of the Brain. Free Radic. Biol. Med. 2013, 63, 1–29.
  28. Joshi, A.U.; Mochly-Rosen, D. Mortal engines: Mitochondrial bioenergetics and dysfunction in neurodegenerative diseases. Pharmacol. Res. 2018, 138, 2–15.
  29. Zhao, X.Y.; Lu, M.H.; Yuan, D.J.; Xu, D.E.; Yao, P.P.; Ji, W.L.; Chen, H.; Liu, W.L.; Yan, C.X.; Xia, Y.Y.; et al. Mitochondrial Dysfunction in Neural Injury. Front. Neurosci. 2019, 13, 30.
  30. Ferramosca, A. Mitochondrial Protein Network: From Biogenesis to Bioenergetics in Health and Disease. Int. J. Mol. Sci. 2021, 22, 1.
  31. Kreimendahl, S.; Schwichtenberg, J.; Günnewig, K.; Brandherm, L.; Rassow, J. The selectivity filter of the mitochondrial protein import machinery. J. BMC Biol. 2020, 18, 156.
  32. Gupta, A.; Becker, T. Mechanisms and pathways of mitochondrial outer membrane protein biogenesis. Biochim. Biophys. Acta Bioenerg. 2020, 1862, 148323.
  33. Horten, P.; Colina-Tenorio, L.; Rampelt, H. Biogenesis of Mitochondrial Metabolite Carriers. Biomolecules 2020, 10, 1008.
  34. Mokranjac, D. How to get to the other side of the mitochondrial inner membrane—The protein import motor. Biol. Chem. 2020, 401, 723–736.
  35. Pfanner, N.; Warscheid, B.; Wiedemann, N. Mitochondrial proteins: From biogenesis to functional networks. Nat. Rev. Mol. Cell Biol. 2019, 20, 267–284.
  36. Sylvester, J.E.; Fischel-Ghodsian, N.; Mougey, E.B.; O’Brien, T.W. Mitochondrial ribosomal proteins: Candidate genes for mitochondrial disease. Genet. Med. 2004, 6, 73–80.
  37. O’Brien, T.W.; O’Brien, B.J.; Norman, R.A. Nuclear MRP genes and mitochondrial disease. Gene 2005, 354, 147–151.
  38. De Silva, D.; Tu, Y.-T.; Amunts, A.; Fontanesi, F.; Barrientos, A. Mitochondrial ribosome assembly in health and disease. Cell Cycle 2015, 14, 2226–2250.
  39. Dickinson, M.E.; Flenniken, A.M.; Ji, X.; Teboul, L.; Wong, M.D.; White, J.K.; Meehan, T.F.; Weninger, W.J.; Westerberg, H.; Adissu, H.; et al. High-throughput discovery of novel developmental phenotypes. Nature 2016, 537, 508–514, Erratum in Nature 2017, 551, 398.
  40. Del Giudice, L.; Alifano, P.; Calcagnile, M.; Di Schiavi, E.; Bertapelle, C.; Aletta, M.; Pontieri, P. Mitochondrial ribosomal protein genes connected with Alzheimer’s and tellurite toxicity. Mitochondrion 2022, 64, 45–58.
  41. Chinnery, P.; Howell, N.; Andrews, R.; Turnbull, D. Clinical mitochondrial genetics. J. Med. Genet. 1999, 36, 425–436.
  42. Fields, M.; Marcuzzi, A.; Gonelli, A.; Celeghini, C.; Maximova, N.; Rimondi, E. Mitochondria-Targeted Antioxidants, an Innovative Class of Antioxidant Compounds for Neurodegenerative Diseases: Perspectives and Limitations. Int. J. Mol. Sci. 2023, 24, 3739.
  43. Stewart, J.B.; Chinnery, P.F. The dynamics of mitochondrial DNA heteroplasmy: Implications for human health and disease. Nat. Rev. Genet. 2015, 16, 530–542.
  44. Gorman, G.S.; Schaefer, A.M.; Ng, Y.; Gomez, N.; Blakely, E.L.; Alston, C.L.; Feeney, C.; Horvath, R.; Yu-Wai-Man, P.; Chinnery, P.F.; et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann. Neurol. 2015, 77, 753–759.
  45. Baker, M.J.; Crameri, J.J.; Thorburn, D.R.; Frazier, A.E.; Stojanovski, D. Mitochondrial biology and dysfunction in secondary mitochondrial disease. Open Biol. 2022, 12, 220274.
  46. Burté, F.; Carelli, V.; Chinnery, P.F.; Yu-Wai-Man, P. Disturbed mitochondrial dynamics and neurodegenerative disorders. Nat. Rev. Neurol. 2015, 11, 11–24.
  47. Islam, M.T. Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders. Neurol. Res. 2017, 39, 73–82.
  48. Baker, B.M.; Haynes, C.M. Mitochondrial protein quality control during biogenesis and aging. Trends Biochem. Sci. 2011, 36, 254–261.
  49. Moehle, E.A.; Shen, K.; Dillin, A. Mitochondrial proteostasis in the context of cellular and organismal health and aging. J. Biol. Chem. 2019, 294, 5396–5407.
  50. Holt, I.; Harding, A.E.; Morgan-Hughes, J.A. Deletion of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988, 331, 717–719.
  51. Birtel, J.; von Landenberg, C.; Gliem, M.; Gliem, C.; Reimann, J.; Kunz, W.S.; Herrmann, P.; Betz, C.; Caswell, R.; Nesbitt, V.; et al. Mitochondrial Retinopathy. Ophthalmol. Retin. 2022, 6, 65–79.
  52. Tsang, S.H.; Aycinena, A.R.; Sharma, T. Mitochondrial Disorder: Kearns-Sayre Syndrome. Adv. Exp. Med. Biol. 2018, 1085, 161–162.
  53. Zeviani, M.; Carelli, V. Mitochondrial Retinopathies. Int. J. Mol. Sci. 2022, 23, 210.
  54. Cormier, V.; Rötig, A.; Quartino, A.R.; Forni, G.L.; Cerone, R.; Maier, M.; Saudubray, J.-M.; Munnich, A. Widespread multitissue deletions of the mitochondrial genome in Pearsons marrow-pancreas syndrome. J. Pediatr. 1990, 117, 599–602.
  55. Yoshimi, A.; Ishikawa, K.; Niemeyer, C.; Grünert, S.C. Pearson syndrome: A multisystem mitochondrial disease with bone marrow failure. Orphanet J. Rare Dis. 2022, 17, 379.
  56. Ballinger, S.W.; Shoffner, J.M.; Hedaya, E.V.; Trounce, I.; Polak, M.A.; Koontz, D.A.; Wallace, D.C. Maternally transmitted diabetes and deafness associated with a 10.4 kb mitochondrial DNA deletion. Nat. Genet. 1992, 1, 11–15.
  57. Yang, M.; Xu, L.; Xu, C.; Cui, Y.; Jiang, S.; Dong, J.; Liao, L. The Mutations and Clinical Variability in Maternally Inherited Diabetes and Deafness: An Analysis of 161 Patients. Front. Endocrinol. 2021, 12, 728043.
  58. Chalmers, R.M.; Brockington, M.; Howard, R.S.; Lecky, B.R.F.; Morgan-Hughes, J.A.; Harding, A.E. Mitochondrial encephalopathy with multiple mitochondrial DNA deletions. J. Neurol. Sci. 1996, 143, 41–45.
  59. Borgione, E.; Giudice, M.L.; Paola, S.S.; Giuliano, M.; Di Blasi, F.D.; Di Stefano, V.; Lupica, A.; Brighina, F.; Pettinato, R.; Romano, C.; et al. The Mitochondrial tRNASer(UCN) Gene: A Novel m.7484A>G Mutation Associated with Mitochondrial Encephalomyopathy and Literature Review. Life 2023, 13, 554.
  60. Ohno, K.; Tanaka, M.; Sahashi, K. Mitochondrial DNA deletions in inherited recurrent myoglobinuria. Ann. Neurol. 1991, 29, 364–369.
  61. Siciliani Scalco, R.; Gardiner, A.R.; Pitceathly, R.D.; Zanoteli, E.; Becker, J.; Holton, J.L.; Houlden, H.; Jungbluth, H.; Quinlivan, R. Rhabdomyolysis: A genetic perspective. Orphanet J. Rare Dis. 2015, 10, 51.
  62. Fadic, R.; Russell, J.A.; Vedanarayanan, V.V.; Lehar, M.; Kuncl, R.W.; Johns, D.R. Sensory ataxic neuropathy as the presenting feature of a novel mitochondrial disease. Neurology 1997, 49, 239–245.
  63. Okun, M.S.; Bhatti, M.T. SANDO: Another presentation of mitochondrial disease. Am. J. Ophthalmol. 2004, 137, 951–953.
  64. Wallace, D.C.; Singh, G.; Lott, M.T.; Hodge, J.A.; Schurr, T.G.; Lezza, A.M.; Elsas, L.J., 2nd; Nikoskelainen, E.K. Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy. Science 1988, 242, 1427–1430.
  65. Yu-Wai-Man, P.; Chinnery, P.F. Leber Hereditary Optic Neuropathy. 26 October 2000; Updated 11 March 2021. In GeneReviews® Internet; Adam, M.P., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J., Gripp, K.W., Amemiya, A., Eds.; University of Washington: Seattle, WA, USA, 2000. Available online: (accessed on 23 February 2023).
  66. Manfredi, G.; Schon, E.A.; Moraes, C.T.; Bonilla, E.; Berry, G.T.; Sladky, J.T.; DiMauro, S. A new mutation associated with MELAS is located in a mitochondrial DNA polypeptide-coding gene. Neuromuscul. Disord. 1995, 5, 391–398.
  67. Stefanetti, R.J.; Ng, Y.S.; Errington, L.; Blain, A.P.; McFarland, R.; Gorman, G.S. L-Arginine in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes. A Systematic Review. Neurology 2022, 98, e2318–e2328.
  68. Thyagarajan, D.; Shanske, S.; Vazquez-Memije, M.; De Vivo, D.; DiMauro, S. A novel mitochondrial ATPase 6 point mutation in familial bilateral striatal necrosis. Ann. Neurol. 1995, 38, 468–472.
  69. Finsterer, J. Neuropathy, Ataxia, and Retinitis Pigmentosa Syndrome. J. Clin. Neuromuscul. Dis. 2023, 24, 140–146.
  70. Shoffner, J.M.; Lott, M.T.; Lezza, A.M.; Seibel, P.; Ballinger, S.W.; Wallace, D.C. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell 1990, 61, 931–937.
  71. Velez-Bartolomei, F.; Lee, C.; Enns, G. GeneReviews® Internet; Adam, M.P., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., Amemiya, A., Eds.; University of Washington: Seattle, WA, USA, 1993.
  72. Taylor, R.W.; Chinnery, P.F.; Bates, M.J.; Jackson, M.J.; Johnson, M.A.; Andrews, R.M.; Turnbull, D.M. A novel mitochondrial DNA point mutation in the tRNA(Ile) gene: Studies in a patient presenting with chronic progressive external ophthalmoplegia and multiple sclerosis. Biochem. Biophys. Res. Commun. 1998, 243, 47–51.
  73. Chalmers, R.M.; Lamont, P.J.; Nelson, I.; Ellison, D.W.; Thomas, N.H.; Harding, A.E.; Hammans, S.R. A mitochondrial DNA tRNA(Val) point mutation associated with adult-onset Leigh syndrome. Neurology 1997, 49, 589–592.
  74. Rahman, S. Leigh syndrome. Handb. Clin. Neurol. 2023, 194, 43–63.
  75. Beal, M.F. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 2005, 58, 495–505.
  76. Jia, F.; Fellner, A.; Kumar, K.R. Monogenic Parkinson′s Disease: Genotype, Phenotype, Pathophysiology, and Genetic Testing. Genes 2022, 13, 471.
  77. Keita, M.; McIntyre, K.; Rodden, L.N.; Schadt, K.; Lynch, D.R. Friedreich ataxia: Clinical features and new developments. Neurodegener. Dis. Manag. 2022, 12, 267–283.
  78. Stoker, T.B.; Mason, S.L.; Greenland, J.C.; Holden, S.T.; Santini, H.; Barker, R.A. Huntington′s disease: Diagnosis and management. Pract. Neurol. 2022, 22, 32–41.
  79. Chia, R.; Chiò, A.; Traynor, B.J. Novel genes associated with amyotrophic lateral sclerosis: Diagnostic and clinical implications. Lancet Neurol. 2018, 17, 94–102.
  80. Hetland, L.E.; Susrud, K.S.; Lindahl, K.H.; Bygum, A. Henoch-Schönlein Purpura: A Literature Review. Acta Derm. Venereol. 2017, 97, 1160–1166.
  81. López-Otín, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. Hallmarks of aging: An expanding universe. Cell 2023, 186, 243–278.
  82. Greiner, S.; Lehwark, P.; Bock, R. OrganellarGenomeDRAW (OGDRAW) version 1.3.1: Expanded toolkit for the graphical visualization of organellar genomes. Nucleic Acids Res. 2019, 47, W59–W64.
  83. Prince, M.; Bryce, R.; Albanese, E.; Wimo, A.; Ribeiro, W.; Ferri, C.P. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimer’s Dement 2013, 9, 63–75.
  84. Prince, M.; Guerchet, M.; Prina, M. The Epidemiology and Impact of Dementia: Current State and Future Trends. 2015. Available online: (accessed on 26 March 2015).
  85. Norfray, J.F.; Provenzale, J.M. Alzheimer’s Disease: Neuropathologic Findings and Recent Advances in Imaging. Am. J. Roentgenol. 2004, 182, 3–13.
  86. Selkoe, D.J. Alzheimer’s disease: Genes, proteins, and therapy. Physiol. Rev. 2001, 81, 741–766.
  87. Seynnaeve, D.; Del Vecchio, M.; Fruhmann, G.; Verelst, J.; Cools, M.; Beckers, J.; Mulvihill, D.P.; IWinderickx, J.; Franssens, V. Recent Insights on Alzheimer’s Disease Originating from Yeast Models. Int. J. Mol. Sci. 2018, 19, 1947.
  88. Monzio Compagnoni, G.; Di Fonzo, A.; Corti, S.; Comi, G.P.; Bresolin, N.; Masliah, E. The Role of Mitochondria in Neurodegenerative Diseases: The Lesson from Alzheimer′s Disease and Parkinson’s Disease. Mol. Neurobiol. 2020, 57, 2959–2980.
  89. Dhapola, R.; Sarma, P.; Medhi, B.; Prakash, A.; Reddy, D.H. Recent Advances in Molecular Pathways and Therapeutic Implications Targeting Mitochondrial Dysfunction for Alzheimer’s Disease. Mol. Neurobiol. 2022, 59, 535–555.
  90. Cummings, J.L.; Tong, G.; Ballard, C. Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options. J. Alzheimers 2019, 67, 779–794.
  91. Ciurea, V.A.; Covache-Busuioc, R.A.; Mohan, A.G.; Costin, H.P.; Voicu, V. Alzheimer’s disease: 120 years of research and progress. J. Med. Life 2023, 16, 173–177.
  92. Poewe, W.; Seppi, K.; Tanner, C.M.; Halliday, G.M.; Brundin, P.; Volkmann, J.; Schrag, A.E.; Lang, A.E. Parkinson dis-ease. Nat. Rev. Dis. Prim. 2017, 3, 17013.
  93. Bloem, B.R.; Okun, M.S.; Klein, C. Parkinson’s disease. Lancet 2021, 397, 2284–2303.
  94. Surmeier, D.J. Determinants of Dopaminergic Neuron Loss in Parkinson′s Disease. FEBS J. 2018, 285, 3657–3668.
  95. Masato, A.; Plotegher, N.; Boassa, D.; Bubacco, L. Impaired dopamine metabolism in Parkinson’s disease pathogenesis. Mol. Neurodegener. 2019, 14, 35.
  96. Checler, F.; Alves da Costa, C. Parkin as a Molecular Bridge Linking Alzheimer’s and Parkinson’s Diseases? Biomolecules 2022, 12, 559.
  97. Liu, Z.; Yang, N.; Dong, J.; Tian, W.; Chang, L.; Ma, J.; Guo, J.; Tan, J.; Dong, A.; He, K.; et al. Deficiency in endocannabinoid syn-thase DAGLB contributes to early onset Parkinsonism and murine nigral dopaminergic neuron dysfunction. Nat. Commun. 2022, 13, 3490.
  98. Kumar, K.R.; Lohmann, K.; Klein, C. Genetics of Parkinson disease and other movement disorders. Curr. Opin. Neurol. 2012, 25, 466–474.
  99. Zhou, X.; Xiang, Y.; Song, T.; Zhao, Y.; Pan, H.; Xu, Q.; Chen, Y.; Sun, Q.; Wu, X.; Yan, X.; et al. Character-istics of fatigue in Parkinson’s disease: A longitudinal cohort study. Front. Aging Neurosci. 2023, 15, 1133705.
  100. Scaltsoyiannes, V.; Corre, N.; Waltz, F.; Giegé, P. Types and Functions of Mitoribosome-Specific Ribosomal Proteins across Eukaryotes. Int. J. Mol. Sci. 2022, 23, 3474.
  101. Sharma, M.R.; Booth, T.M.; Simpson, L.; Maslov, D.A.; Agrawal, R.K. Structure of a mitochondrial ribosome with minimal RNA. Proc. Natl. Acad. Sci. USA 2009, 106, 9637–9642.
  102. Greber, B.J.; Bieri, P.; Leibundgut, M.; Leitner, A.; Aebersold, R.; Boehringer, D.; Ban, N. Ribosome. The complete structure of the 55S mammalian mitochondrial ribosome. Science 2015, 348, 303–308.
  103. Amunts, A.; Brown, A.; Toots, J.; Scheres, S.H.W.; Ramakrishnan, V. The structure of the human mitochondrial ribosome. Science 2015, 348, 95–98.
  104. Greber, B.J.; Ban, N. Structure and Function of the Mitochondrial Ribosome. Annu. Rev. Biochem. 2016, 85, 103–132.
  105. Mai, N.; Chrzanowska-Lightowlers, Z.M.A.; Lightowlers, R.N. The process of mammalian mitochondrial protein synthesis. Cell Tissue Res. 2017, 367, 5–20.
  106. Ferrari, A.; Del’olio, S.; Barrientos, A. The Diseased Mitoribosome. FEBS Lett. 2021, 595, 1025–1061.
  107. Vafai, S.B.; Mootha, V.K. Mitochondrial disorders as windows into an ancient organelle. Nature 2012, 491, 374–383.
  108. Boczonadi, V.; Horvath, R. Mitochondria: Impaired mitochondrial translation in human disease. Int. J. Biochem. Cell Biol. 2014, 48, 77–84.
  109. Rotig, A. Human diseases with impaired mitochondrial protein synthesis. Biochim. Biophys. Acta 2011, 1807, 1198–1205.
  110. Boczonadi, V.; Ricci, G.; Horvath, R. Mitochondrial DNA transcription and translation: Clinical syndromes. Essays Biochem. 2018, 62, 321–340.
  111. Lopez Sanchez, M.I.G.; Krüger, A.; Shiriaev, D.I.; Liu, Y.; Rorbach, J. Human Mitoribosome Biogenesis and Its Emerging Links to Disease. Int. J. Mol. Sci. 2021, 22, 3827.
  112. Greber, B.J.; Boehringer, D.; Leibundgut, M.; Bieri, P.; Leitner, A.; Schmitz, N.; Aebersold, R.; Ban, N. The complete structure of the large subunit of the mammalian mitochondrial ribosome. Nature 2014, 515, 283–286.
  113. Lake, N.J.; Bird, M.J.; Isohanni, P.; Paetau, A. Leigh Syndrome: Neuropathology and Pathogenesis. J. Neuropathol. Exp. Neurol. 2015, 74, 482–492.
  114. Lin, M.T.; Beal, M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443, 787–795.
  115. Danial, N.N.; Korsmeyer, S.J. Cell Death: Critical Control Points. Cell 2004, 116, 205–219.
  116. Scarpelli, M.; Todeschini, A.; Volonghi, I.; Padovani, A.; Filosto, M. Mitochondrial diseases: Advances and issues. Appl. Clin. Genet. 2017, 10, 21–26.
  117. Filosto, M.; Mancuso, M. Mitochondrial diseases: A nosological update. Acta Neurol. Scand. 2007, 115, 211–221.
  118. Nafisinia, M.; Guo, Y.; Dang, X.; Li, J.; Chen, Y.; Zhang, J.; Lake, N.J.; Gold, W.A.; Riley, L.G.; Thorburn, D.R.; et al. Whole Exome Sequencing Identifies the Genetic Basis of Late-Onset Leigh Syndrome in a Patient with MRI but Little Biochemical Evidence of a Mitochondrial Disorder. JIMD Rep. 2017, 32, 117–124.
  119. Taylor, S.W.; Fahy, E.; Zhang, B.; Glenn, G.M.; Warnock, D.E.; Wiley, S.; Murphy, A.N.; Gaucher, S.P.; Capaldi, R.A.; Gibson, B.W.; et al. Characterization of the human heart mitochondrial proteome. Nat. Biotechnol. 2003, 21, 281–286.
  120. Lescuyer, P.; Strub, J.M.; Luche, S.; Diemer, H.; Martinez, P.; Van Dorsselaer, A.; Lunardi, J.; Rabilloud, T. Progress in the defi-nition of a reference human mitochondrial proteome. Proteomics 2003, 3, 157–167.
  121. Uechi, T.; Tanaka, T.; Kenmochi, N. A complete map of the human ribosomal proteingenes: Assignment of 80 genes to the cytogenetic map and implications for human disorders. Genomics 2001, 72, 223–230.
  122. Melnikov, S.; Ben-Shem, A.; De Loubresse, N.G.; Jenner, L.; Yusupova, G.; Yusupov, M. One core, two shells: Bacterial and eukaryotic ribosomes. Nat. Struct. Mol. Biol. 2012, 19, 560–567.
  123. Kressler, D.; Hurt, E.; Baßler, J. A Puzzle of Life: Crafting Ribosomal Subunits. Trends Biochem. Sci. 2017, 42, 640–654.
  124. Sissler, M.; Hashem, Y. Mitoribosome assembly comes into view. Nat. Struct. Mol. Biol. 2021, 28, 631–633.
  125. Robles, P.; Quesada, V. Emerging Roles of Mitochondrial Ribosomal Proteins in Plant Development. Int. J. Mol. Sci. 2017, 18, 2595.
  126. DiMauro, S.; Schon, E.A. Mitochondrial Respiratory-Chain Diseases. N. Engl. J. Med. 2003, 348, 2656–2668.
  127. O′Brien, T.W. Properties of Human Mitochondrial Ribosomes. IUBMB Life 2003, 55, 505–513.
  128. Kenmochi, N.; Suzuki, T.; Uechi, T.; Magoori, M.; Kuniba, M.; Higa, S.; Watanabe, K.; Tanaka, T. The Human Mitochondrial Ribosomal Protein Genes: Mapping of 54 Genes to the Chromosomes and Implications for Human Disorders. Genomics 2001, 77, 65–70.
  129. Yeo, J.H.C.; Skinner, J.P.J.; Bird, M.; Formosa, L.E.; Zhang, J.-G.; Kluck, R.M.; Belz, G.T.; Chong, M.M.W. A Role for the Mitochondrial Protein Mrpl44 in Maintaining OXPHOS Capacity. PLoS ONE 2015, 10, e0134326.
  130. Verity, M.A. Environmental neurotoxicity of chemicals and radiation. Curr. Opin. Neurol. Neurosurg. 1993, 6, 437–442.
  131. Larner, A.J. Alzheimer’s disease, Kuf ’s disease, tellurium and selenium. Med. Hypotheses 1996, 47, 73–75.
  132. Larner, A.J. Biological effects of tellurium, A review. Trace Elem. Electrolytes 1995, 12, 26–31.
  133. Pontieri, P.; De Stefano, M.; Massardo, D.R.; Gunge, N.; Miyakawa, I.; Sando, N.; Pignone, D.; Pizzolante, G.; Romano, R.; Alifano, P.; et al. Tellurium as a valuable tool for studying the prokaryotic origins of mitochondria. Gene 2015, 559, 177–183.
  134. Pontieri, P.; Hartings, H.; Salvo, M.D.; Massardo, D.R.; Stefano, M.D.; Pizzolante, G.; Romano, R.; Troisi, J.; Giudice, A.D.; Alifano, P.; et al. Mitochondrial ribosomal proteins involved in tellurite resistance in yeast Saccharomyces cerevisiae. Sci. Rep. 2018, 8, 12022.
Subjects: Biology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to : , , ,
View Times: 229
Revisions: 2 times (View History)
Update Date: 19 Jul 2023
Video Production Service